Get this report today!
Table of Contents
Across the globe, regulators continue to develop the approval pathways and guidance regarding biosimilars. In the US, the FDA is currently consulting with various stakeholders regarding details of the US biosimilars pathway. While in the EU, the EMA is furthering development of approval pathways for biosimilar monoclonal antibodies
Features and benefits
* Provides global biosimilar sales (2008–10), in addition to the status of biosimilar approval pathways across the globe.
* Insight into the key biosimilar regulatory developments in the US, EU and emerging markets
Since the US biosimilars pathway leaves many of the details for approval up to the FDA, the regulator has sought consultation, with discussion focusing on user fees, interchangeability, comparative studies and exclusivity, among other issues.
In Europe, the European Medicines Agency (EMA) has been seeking to develop further guidance for more technically challenging products such as monoclonal antibodies, while UK regulatory authorities have given their backing for the use of number of biosimilars in the national health services of England and Scotland.
The Brazilian government has also shown willingness to embrace biosimilars in an effort to reduce ever-increasing government healthcare expenditure. However, in contrast, a number of biosimilars have been removed from the substitution list in Norway, following a court ruling.
Your key questions answered
* Evaluate the evolving regulatory environment around the world, and how this impacts biosimilar market access and uptake.
* Gain insight into the strategies employed by payers and pharmaceutical companies in response to these changes in the regulatory environment.
Talk to Robyn
00 1 718 213 49 04
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
"Analytical Tool - Antibodies and Peptides in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in the antibody and ...
Proteins exhibit high specificity and less immunogenicity and are widely used as therapeutic agents in the treatment of various disorders and diseases. There are more than 200 protein-based products currently ...
This triple analysis focuses on cancer drug development strategies by the mechanism/target/effect of Cancer Vaccines and by the two compound strategies of Antibodies and Peptides. Each of these three individual ...
... Production Preparation of enzymes 21/03/2013 why enzymes Catalysts increase the rate of reactions without any net change in their structure. Concept of catalysis is developed as early as the 19th ...
... Alfa was non-inferior to imiglucerase if the lower limit of the one-sided 97.5% Confidence interval (ci) of the treatment difference (velaglucerase alfa minus imiglucerase) was greater than -1 g ...
... E in upstream and downstream development. As an example of pharmaceutical proteins whole production processes of potential malaria vaccines are investigated in detail. In the field of technical enzymes ...
Reportlinker.com © Copyright 2013. All rights reserved.